Introduction
Patients with drug resistant epilepsy (DRE) may be referred to an Epilepsy Surgery Programme but some are not suitable for resective surgery for their epilepsy [1] [2] [3] . This is due to a number of factors including poor localisation of lesions, the location of seizures, and co-morbidities [4] . The palliative procedures available for such cases include corpus callosotomy, stimulation of the vagus nerve, deep brain stimulation and transcranial magnetic stimulation. Of these palliative procedures Vagus Nerve Stimulation (VNS Therapy 1 , Cyberonics Inc. Houston TX, USA) has gained widespread popularity and in excess of 80,000 devices world-wide have been implanted in DRE patients in the last 20 years. Vagus nerve stimulation (VNS) can reduce seizures in some patients with DRE [5] and yet there is a variable referral rate for assessment for VNS therapy.
The pattern of under-referral is reported internationally with referral for surgical assessment in Sweden estimated to be underused in individuals with focal drug resistant epilepsy [6] . In the USA trends in lobectomy between 1990 and 2008 suggests underutilisation despite a doubling in hospitalisations in that period for DRE [7] . A retrospective study suggests that referral may be increasing in line with recommendations from the American Academy of Neurology (AAN) [8] . A survey of neurologists in the UK highlighted an overall reduction of adult surgical treatments from a total of 578 in 2000 to 472 in 2011. There was an almost 50% drop in lesional resection with an increase in neuromodulatory procedures from 156 to 230 [9] . In children the picture may be different with a single centre study from Holland showing an increase in resective surgery each year from 1990 to 2011 [10] .
The pattern of VNS use in England is interesting in that while the number of resective surgery procedures fell in the first decade of this century, the numbers of VNS implantations in the UK in adults increased [9] . VNS now accounts for over half of epilepsy surgery procedures (55.2%) of which 69% were performed in 6 large university centres [9] . In England and Wales VNS implantation has risen from 148 new implants in 2009 to 246 in 2013 with some centres implanting over 50 devices in this period and some less than 10 devices. There was also an associated increase in battery replacements with 81 in 2009 and 302 in 2013. This is in line with guidance in the UK [11] that recommend VNS as a treatment for both focal and generalised seizures in children and adults. In the USA guidance recommends consideration of VNS for Lennox Gaustaut Syndrome (LGS) because the responder rates for patients with LGS appears not to differ from the general population of patients with drug resistant epilepsy [12] .
The factors affecting the variable referral rate for VNS assessment are not known. Clearly, the therapy is effective in the majority of recipients although some patients do not respond [5, 13, 14] but treatment costs may be a factor.
The costs of assessment and implantation are significant but in the USA, the device costs are balanced by a reduction in health care utilisation costs with the breakeven point being after 18 months of therapy overall but with a more rapid break-even point of 12 months for 12-18 year olds [15, 16] . It is not clear whether this picture would transfer from the American mixed model health system where health expenditure costs 16.9% of GDP in 2010 to the UK system where there is a cost contained single tier taxation based Beveridge health system [17] costing 9.3% of GDP [18] .
With the increasing use of VNS Therapy in the UK, It is also timely to explore the clinical impact of VNS given the relationship of seizure frequency to hospital utilisation [19] and the evidence relating to seizure reduction with VNS Therapy [7, 15, 20] . The NHS Commissioning Board, recognising that 'patients with refractory epilepsy require more out-patient clinic time, combination therapy (often with newer, expensive anti-epileptic drugs) and hospitalisation' developed a commissioning policy for VNS to ensure more equitable provision of services [21] . This policy should be welcomed by commissioners who are aware of the increasing burden of non-elective activity on the NHS [22] [23] [24] [25] and a reported 12% increase in Accident and Emergency (A&E) attendance in the last decade [26] . This study assessed the effect of VNS Therapy on hospital utilisation.
Methods
A before and after health utilisation study was performed on 321 anonymised patients who received VNS Therapy in NHS hospitals in the UK between April 2009 and July 2011 of which nearly half (n = 123) were implanted in 3 centres (Bristol, Kings College London and Sheffield).
Hospital Episode Statistics (HES) data of elective and nonelective in-patient admissions and out-patient appointments and also A&E department attendances and disposal were analysed in the secondary care setting, activity 12 months prior and 36 months following VNS implantation were compared. Per-quarter average resource use was evaluated in order to provide a normalised measure of resource use for comparison across unequal windows of observation (see Fig. 1 ).
Patients were identified for inclusion in the sample using a combination of diagnosis and intervention codes. To determine that the patient had undergone VNS implantation to treat epilepsy, they had to have an in-patient or out-patient record between April 2006 and July 2014 containing diagnosis codes G40 'Epilepsy' and/ or G41 'Status epilepticus'. April 2006 was the earliest point from which patient data was available, and so data from this point was included in the identification window to ensure the largest pool of epilepsy patients possible.
In addition they also had to have an in-patient or out-patient record between April 2009 and July 2011 containing procedure code A33.1 'Introduction of neurostimulator into cranial nerve' and the site of intervention code Z04.4 'Vagus nerve (x)'. Transcutaneous stimulator (OPCS code Y90.1) was not included in the study sample.
Patients with a VNS implantation date between 1st April 2009 and 31st July 2011 were selected in order to ensure that all patients had at least the required observation period for comparison (one year prior and three years post VNS implantation). Reliable A&E data is available from 1st April 2008 so an inclusion date of 1st April 2009 was required in order to allow all patients at least four quarters of reliable A&E attendance data.
Patient resource utilisation was calculated retrospectively and normalised to average (mean) visits/days per quarter. This allows fair comparison of the pre-VNS of 12 months and post-VNS period of 36 months, taking into account the unequal window of observation in the two periods. Resource use before and after VNS was identified outside of the episode of implantation, so resource use attributed to either the 'before' or 'after' intervention period did not include the in-patient episode in which the patient received the implant. To match the American study [13] , each patient's observation period extended from the index date until removal of the device, death or end of the study period (maximum 3 years of follow-up), whichever occurred first.
Data analysis
Descriptive statistics were used to summarise patient demographics, patient pathways, and VNS usage and to assess resource use comparing the before and after VNS periods. Means and proportions were reported on continuous variables, proportion and frequency on categorical variables. Trends of activity over time were determined comparing the average quarterly resource use before VNS and quarterly resource use data following VNS. This trend data was subsequently tested using the Wilcoxon Fig. 1 . Study design.
Signed-rank (WSR) test. The WSR test is the non-parametric equivalent to the t-test, and was used to test for statistically significant differences in resource use following VNS, relative to a baseline of average (quarterly) resource use prior to VNS in terms of in-patient bed-days, elective in-patient, non-elective in-patient, out-patient and A&E visits ( Table 1 ). The WSR test provides an alternative measure of change across the before and after VNS periods that is not influenced by extreme outliers that may be captured in the data. The WSR was used in order to evaluate the sensitivity of outputs from descriptive statistics to the assumption of a normal distribution in outcome data.
Results
The study population of 321 VNS users was 52% male with an age range from 2 to 75 and a mean age of 27.8 years (n = 320 with one missing value) with 118 patients age 19 years or less, 117 age 20-39 years, 77 age between 40 and 59 years and 9 patients age 60 years and older. The first VNS implantation was recorded 1st April 2009 and the last recorded 29th July 2011 giving a total of 17,317 observations of which there were 4019 observations before VNS and 12,997 after. Before and after VNS elective and non-elective episodes per quarter were compared for in-patient bed days, out-patient appointments and A&E attendances ( Table 2) . The summary statistics, based on mean quarterly utilisation, indicate that there has been a drop in resource use when comparing the before and after VNS periods in terms of in-patient bed-days (21% decrease), elective in-patient episodes (7% decrease) and non-elective in-patient episodes (14% decrease). There was an increase in the quarterly average out-patient appointments by 12% possibly due to routine post-surgical follow-up and device management.
A&E attendance was found to be influenced by a small number of patients non-responsive to VNS, who experienced a high volume of A&E attendance in the follow up period resulting in an increase reported from the summary statistics. Further investigation into the A&E outcome variable revealed there is uncertainty in results shown from descriptive summary statistics alone for this outcome, given a skewed distribution of A&E attendances.
The clinical codes reported most commonly by 4 frequent attenders of A&E were examined and are included later.
The results of the WSR test demonstrated a statistically significant (p < 0.05) decline in resource use comparing before and after VNS implant in all 12 quarters following intervention across in-patient bed-days, non-elective in-patient episodes and elective in-patient episodes. The WSR test reported a statistically significant decline in A&E attendance in all quarters following VNS with the exception of quarter 10 which reported a decline, however failed to reach significance level p < 0.05 (p-value 0.07). The out-patient appointments results showed increase in resource use following VNS until quarter 8 where we see a statistically significant decline (Table 1) .
In-patient admission data
Episodic data collected from in-patient spells (the duration of in-patient care) show 611 observed episodes before VNS and 1640 episodes after (mean 152.8 and 136.7 per quarter, respectively). 374 non-elective episodes were captured before VNS and 954 after (mean 93.5 and 79.5 per quarter, respectively). A small decrease was seen in elective episodes also, with 237 episodes before VNS and 686 after (mean 59.25 and 57.17 per quarter, respectively). There was a reduction in mean quarterly in-patient bed-days by 21% from a quarterly average of 1.34 before VNS to a quarterly average of 1.06 after.
Elective activity
There were 686 elective admissions after VNS with a mean of 57 per quarter. The primary diagnoses for the elective admissions other than codes for generalised or localisation-related epilepsy was for holiday relief care. There was a shift in the ratio of elective to non-elective in-patient episodes following VNS, with an increase in elective and an equivalent decrease in non-elective episodes.
Non-elective activity
There were 954 non-elective in-patient episodes after VNS (mean 80 per quarter) with a decrease in mean per-quarter nonelective episodes from 0.31 before VNS to 0.26 after (Fig. 2) . There was a modest rise in the first 6 months after implant and then a steady decrease. Coding was incomplete in many cases but from available data, the majority of primary diagnostic codes for the non-elective episodes were related to epilepsy including 10 episodes coded as status epilepticus.
Out-patient appointments
Out-patient coding is also incomplete in 95% of appointments. The management of device settings and duty cycles after device implantation may require some additional appointments. The quarterly trend data indicate that this increase flattens after 18 months following VNS to a level just below the mean appointment frequency across the before VNS period. The mean quarterly number of appointments over the study period is 2.27 appointments before and 2.54 appointments after VNS. The majority (70%) of appointments after VNS were with epilepsy related specialities including neurology, neurosurgery, paediatric neurology or paediatrics and around 10% of appointments were with trauma/orthopaedics or mental illness specialists.
The mean number of quarterly out-patient appointments in the 12 quarters following implant showed a significant rise in activity particularly in the first 3 months. The increase continues for 3 quarters after VNS with the activity returning to levels seen before VNS at quarter 6, with a small decrease recorded between quarter 6 and quarter 12. When the activity for device maintenance was plotted for the 3 years following implant, it shows a gradual reduction from 26 episodes in the first year to 10 episodes in the second year with a rise in the 3rd year to 25 episodes (Fig. 3 ). There were 8 devices removed, one in the first year, 4 in the second year and 3 in the third year. No information was recorded about the reason for removal.
Accident & Emergency (A&E) Department attendance
The number of A&E attendances recorded before VNS was 506 (mean 127 per quarter) and 1635 after (mean 137 per quarter). In the period before VNS one patient attended 10 times in a single quarter and another patient attended 9 times within a quarter. In the period after VNS, there were patients who attended between 10 and 16 times in a single quarter. The majority of patients did not visit A&E, with between 72 and 77% not attending each quarter following implant. The A&E attendance figures were therefore skewed by a small number of frequent attenders with 3% or less attending A&E 4 times or more a quarter.
When the A&E data was tested using the Wilcoxon Sign-Rank (WSR) test the results showed a decrease in A&E resource use in each quarter following implant when compared against the average quarterly attendance before VNS, with only quarter 10 failing to reach a significance level of p < 0.05 (Table 1) . The WSR test results indicated a decrease in resource use, but this is contradictory to what we find looking at the descriptive statistics alone and is likely a good indicator that the mean is not an effective measure of average resource use for A&E attendance outcome. Given the skewed nature of the A&E outcome, and the contradiction across various statistical measures of average resource use, we approach the results of A&E activity with caution.
Aggregated numbers of attendances in the 3 years after VNS showed that only 3 patients attended more than 35 times in the 3 years after VNS and one outlier attended 94 times. The diagnostic codes of these 4 most frequent attenders were examined.
The first patient attended A&E a total of 94 times in the 3 years after implant. The primary diagnostic codes for the visits showed that in over half the visits, the diagnosis was 'not classifiable', only 20% coded as 'central nervous system conditions-epilepsy' with 25% coded as 'other non-epilepsy', 'psychiatric conditions', and 'dissociative (conversion) disorders'. This suggests that this patient experiences refractory seizures of a non-epileptic origin and so would not respond to the device.
The next patient attended A&E 7 times in a single quarter after VNS and the primary diagnoses included 'gastrointestinal conditions-acute abdominal pain' and gastrointestinal conditionsother', 'urological conditions (including cystitis)' and 'social problem'. In the 19 diagnostic observation codes, only 2 stated 'central nervous system-epilepsy' and so it appears that epilepsy was not the clinical problem in the 7 A&E visits.
The 3rd frequent attender had diagnostic codes suggesting severe trauma including lacerations, burns and dislocation/ fractures. The 4th case attended with the majority of codes being related to epilepsy. It is possible that these two cases are VNS nonresponders.
An estimate of the severity of injury causing A&E attendance was made by assigning trauma codes recorded to 'serious' or 'nonserious' categories for comparison over the before and after VNS periods (Fig. 4) . A&E attendances with a discernible diagnosis were included, with 571 observations before VNS (mean 93 per quarter) and 1429 observations after (mean 61 per quarter).
The codes considered 'Serious trauma' were head injury, fracture, burns/scalds, laceration and the non-serious or 'Mild trauma' codes were sprain/ligament injury, contusion, soft tissue inflammation. The number of 'Serious trauma' codes demonstrated a reduction from 26% to 18% of observations when comparing before and after VNS, respectively. The disposal codes of patients in A&E were compared before (1087 observations, mean 272 per quarter) and after (2308 observations, mean 193 per quarter) VNS implant. There was little difference in disposal pathways with over half being discharged without follow-up or follow-up by the general practitioner and around a third of patients being 'admitted'.
Discussion
The Hospital Episode Statistics dataset from the NHS in England captures complete hospital activity for all patients treated with a VNS Therapy device and provides details of both elective and nonelective episodes. VNS Therapy appears to reduce the number of episodes of unscheduled admission and bed days but the impact on A&E attendance is equivocal. It would also appear to result in increased outpatient activity. Inpatient data shows a change in the ratio of elective to non-elective admissions with a decrease in the proportion of non-elective admissions. Planned activity benefits both the patient and the health service and is an important criteria when commissioning health services.
While the HES dataset gives full episodic data, the clinical coding was often incomplete and so the reasons for the reduction in resource use after implant are uncertain. However, the reduction in bed days and serious trauma may be a surrogate measure for reduced seizure severity.
The A&E data were skewed with the majority of patients (over 70%) not attending and less than 3% attending 4 times or more per quarter. The mean attendance rose after VNS and the clinical codes of the most frequent attenders suggested attendance was due to conditions in part not related to epilepsy. Non-parametric analysis suggests that attendance may reduce after implant but these results should be treated with caution. Clinical coding allowed A&E attendance to be ranked as due to either 'serious' or 'non-serious' Fig. 4 . Proportion of codes that were contained within the 'Serious trauma' and 'Mild trauma' categories assigned, before and after VNS.
trauma with the proportion of serious trauma falling after VNS treatment. The WSR test provides an alternative measure of change across the before and after VNS periods that is not influenced by extreme outliers that may be captured in the data. An analysis of means after removal of outliers was considered but there was no obvious cut point and it is difficult to avoid bias if data was manipulated in this way. The national trend in overall A&E activity in England during the study period showed an increase and this was not factored into the before and after analysis.
Outpatient activity increased after implant and this is to be expected due to the programming and monitoring of the devices. The management of the device is tailored to the patient and guidance recommends between 6 to 8 additional outpatient clinic attendances for individualisation of the settings over the first 12 months following implantation [18] . These visits are assumed to be over and above the bi-annual visits that every patient with epilepsy would routinely attend each year. In the UK, device programming is done by members of the multi-disciplinary team [21] . This is a significant workload and has to be planned carefully using the expertise found in specialist units. VNS Therapy may be effective for some patients but with the marginal hospital activity benefits after implant, it is important to select patients most likely to respond to the treatment and this selection may be best performed in centres with a dedicated Multi-Disciplinary Team.
Conclusion
This study compares hospital utilisation in patients with DRE before and after initiation of VNS Therapy in an English sample using data for 1 year before and 3 years after implant. There is a small decrease in some elective and non-elective episodes but the most noticeable changes are in a reduction of episodes of unscheduled care and length of hospital stay. There is an increase in mean A&E attendance after implant but the sample is skewed by a small number of frequent attenders and after adjustment there may be a small decrease in attendance after VNS. There is a decrease in serious trauma after VNS. There is an increase in outpatient episodes associated with device programming.
The study has limitations. The clinical coding was inadequate and did not allow for a detailed analysis of either out-patient or inpatient episodes. The uncertainty around the statistical tests reported on A&E data means that although analysis may show a reduction in activity the results should be treated with caution.
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